6.
Loke H, Bethell D, Phuong C, Dung M, Schneider J, White N
. Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?. J Infect Dis. 2001; 184(11):1369-73.
DOI: 10.1086/324320.
View
7.
Medigeshi G, Islam F, Lodha R
. Quadrivalent dengue-virus vaccines: challenges and opportunities for India. Lancet Infect Dis. 2024; 24(5):e270-e271.
DOI: 10.1016/S1473-3099(24)00137-3.
View
8.
Bauer K, Esquilin I, Santiago Cornier A, Thomas S, Quintero Del Rio A, Bertran-Pasarell J
. A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico. Am J Trop Med Hyg. 2015; 93(3):441-453.
PMC: 4559678.
DOI: 10.4269/ajtmh.14-0625.
View
9.
Mohanty L, Prabhu M, Mishra A, Purty A, Kanungo R, Ghosh G
. Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial. Vaccine X. 2022; 10:100142.
PMC: 8892502.
DOI: 10.1016/j.jvacx.2022.100142.
View
10.
Schouest B, Grifoni A, Pham J, Mateus J, Sydney J, Brien J
. Pre-existing T Cell Memory against Zika Virus. J Virol. 2021; 95(12).
PMC: 8316092.
DOI: 10.1128/JVI.00132-21.
View
11.
Irie K, Mohan P, Sasaguri Y, Putnak R, Padmanabhan R
. Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene. 1989; 75(2):197-211.
DOI: 10.1016/0378-1119(89)90266-7.
View
12.
Mangada M, Rothman A
. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005; 175(4):2676-83.
DOI: 10.4049/jimmunol.175.4.2676.
View
13.
Zivny J, Kurane I, Leporati A, Ibe M, Takiguchi M, Zeng L
. A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities. J Exp Med. 1995; 182(3):853-63.
PMC: 2192165.
DOI: 10.1084/jem.182.3.853.
View
14.
GRUENBERG A, Woo W, Biedrzycka A, Wright P
. Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2, New Guinea C and PUO-218 strains. J Gen Virol. 1988; 69 ( Pt 6):1391-8.
DOI: 10.1099/0022-1317-69-6-1391.
View
15.
Bowerman N, Falta M, Mack D, Kappler J, Fontenot A
. Mutagenesis of beryllium-specific TCRs suggests an unusual binding topology for antigen recognition. J Immunol. 2011; 187(7):3694-703.
PMC: 3178675.
DOI: 10.4049/jimmunol.1101872.
View
16.
Piazza P, Campbell D, Marques E, Hildebrand W, Buchli R, Mailliard R
. Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol. 2014; 177(3):696-702.
PMC: 4137854.
DOI: 10.1111/cei.12373.
View
17.
Lindow J, Borochoff-Porte N, Durbin A, Whitehead S, Fimlaid K, Bunn J
. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis. 2012; 6(7):e1742.
PMC: 3398956.
DOI: 10.1371/journal.pntd.0001742.
View
18.
Livingston P, Kurane I, Dai L, Okamoto Y, Lai C, Men R
. Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol. 1995; 154(3):1287-95.
View
19.
Angelo M, Grifoni A, ORourke P, Sidney J, Paul S, Peters B
. Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. J Virol. 2016; 91(5).
PMC: 5309943.
DOI: 10.1128/JVI.02147-16.
View
20.
Tian Y, Grifoni A, Sette A, Weiskopf D
. Human T Cell Response to Dengue Virus Infection. Front Immunol. 2019; 10:2125.
PMC: 6737489.
DOI: 10.3389/fimmu.2019.02125.
View